Neurocrine to buy Soleno Therapeutics for $2.9 billion
April 6 (Reuters) – Neurocrine Biosciences will purchase uncommon illness drugmaker Soleno Therapeutics for $2.9 billion in money, the businesses stated on Monday, marking the neuroscience-focused drugmaker’s growth into metabolic problems. Neurocrine has provided $53 per Soleno share held, which represents a premium of about 34% to inventory’s final shut. Soleno shares, which had risen…